1 completed. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Completed 1 |
Follow CUDC-907: new trials by email Literature Review of CUDC-907 trials Research Report on CUDC-907
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations CUDC-907 - Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations | Phase 2 | Completed | Curis, Inc. | 70 | 2016-07-01 | 2022-04-27 |
Curis, Inc. (1)
Spain (1) · United States (1)